↓ Skip to main content

Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

Overview of attention for article published in AIDS and Behavior, February 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
95 Mendeley
Title
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Published in
AIDS and Behavior, February 2016
DOI 10.1007/s10461-016-1312-2
Pubmed ID
Authors

Barbara S. Mensch, Elizabeth R. Brown, Karen Liu, Jeanne Marrazzo, Zvavahera Mike Chirenje, Kailazarid Gomez, Jeanna Piper, Karen Patterson, Ariane van der Straten

Abstract

VOICE-a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet (tenofovir or Truvada) or daily use of tenofovir gel in 5029 women from South Africa, Uganda, and Zimbabwe-found none of the drug regimens effective in reducing HIV-1 acquisition in the intent-to-treat analysis. More than half of women assigned to active products in a case cohort sample had no drug detected in any plasma specimens tested during the trial. Yet, in response to questions asked of participants during the trial, ≥90 % of doses were reportedly taken. To explore factors associated with low adherence, a behavioral termination visit questionnaire was developed after early closure of the oral tenofovir and vaginal gel arms. We hypothesized that participants would be more forthcoming about nonuse after they exited the trial than during monthly/quarterly follow-up visits. Comparison of adherence reporting at routine follow-up visits with reporting at trial termination, however, indicates that disclosure of product nonadherence did not increase at the termination visit as anticipated. In resource-limited settings where women value the ancillary benefits provided by trial participation and are concerned that disclosure of nonuse may jeopardize trial participation, objective measures of adherence may yield more meaningful data regarding the inability or reluctance to use than measures of product use derived from self-report.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 95 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 16%
Student > Master 15 16%
Student > Ph. D. Student 11 12%
Student > Postgraduate 5 5%
Student > Bachelor 5 5%
Other 17 18%
Unknown 27 28%
Readers by discipline Count As %
Medicine and Dentistry 23 24%
Nursing and Health Professions 13 14%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Social Sciences 6 6%
Psychology 5 5%
Other 12 13%
Unknown 30 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2017.
All research outputs
#14,405,036
of 23,849,058 outputs
Outputs from AIDS and Behavior
#2,022
of 3,566 outputs
Outputs of similar age
#151,441
of 301,012 outputs
Outputs of similar age from AIDS and Behavior
#50
of 98 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,566 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,012 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.